June 27, 2022
For World Microbiome Day, let’s talk about gut dysbiosis and its detrimental impact in human health.
Clinical Evidence
Find all published clinical trials by therapeutic area and product of interest
i.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life
Lorenzo-Zúñiga V, et al · 2014
Combination of a probiotic and an antispasmodic increases quality of life and reduces symptoms in patients with irritable bowel syndrome: a pilot study
Barraza-Ortiz DA, et al · 2020
Efficacy of probiotic i3.1 symptomatic improvement in patients with lactose intolerance
Cano-Contreras A, et al · 2020
Comparative effect of the i3.1 probiotic formula in two animal models of colitis
Lorén V, et al · 2017
Dedicated to microbiome science
Read updated information about the microbiota and its link with human health
Information intented for Business to Business purpose and health care professionals
May 19, 2022
We are thrilled to announce that our two finalists, AB21® and LipiGO®, have both taken home the crown in their respective categories for this
May 5, 2022
AB-BIOTICS acquired Pharma GMP and Probiotics production facility Alifarm, (Llicè de Vall, Barcelona) to further develop its Probiotics packaging solutions for their customers.
May 5, 2022
AB-BIOTICS releases 2021 financial accounts and General Shareholders Meeting information, Barcelona, at May 5th 2022, AB-BIOTICS has posted call notice
![Mesa de trabajo 1[7305]](https://www.ab-biotics.com/wp-content/uploads/elementor/thumbs/Mesa-de-trabajo-17305-pnzn48q8ee5lgn3bfq8qhxw8288qs9vaj9km98k048.png "Mesa de trabajo 1[7305]")
April 28, 2022
Nutraingredients has announced the finalists for the 8th edition of the awards. We are pleased to announce the nomination of LipiGO® for the Weight
March 21, 2022
Frontiers has published the latest clinical data of AB-KOLICARE™, that shows quite promising results on infant colic. This probiotic formulation leads AB-BIOTICS pediatric line,
